Users Stopping Slimming Injections Put On Pounds Far More Rapidly Than People Using Diet and Exercise

A recent study suggests that patients who stop using blockbuster slimming jabs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who end traditional diet and exercise regimens.

Research printed in a major health publication demonstrates that while overweight people can lose a large proportion of their body weight while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.

"People buying these drugs should be aware of the risk of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.

This pace of recovery implies a reversion to original weight in about one and a half years.

Weighing Therapies

The research, which reviewed dozens of studies involving thousands of participants, contrasted the effects of the injectable medications with older methods.

Researchers emphasize that people who lose weight through lifestyle changes alone generally see a slower weight regain—around 100 grams monthly—post-intervention.

The Reason for the Fast Rebound

Nutrition scientists propose the mechanism of the jabs explains the heightened regain.

GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Sustained high doses of the hormone concentrations far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication leads to hunger is no longer kept in check, making binge eating a significant risk."

An Ongoing Issue?

Health authorities recommend the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.

A number of clinicians contend that, given the high risk of weight regain, the treatment might need to be long-term.

This opinion is reinforced by drug manufacturers, who say that the findings "emphasize the chronic nature of excess weight," similar to managing diseases like diabetes.

User Accounts

Individuals who have stopped the jabs report a sudden resurgence of cravings.

"I experienced a trigger flipping and I was suddenly ravenous," recalled one woman.

This difficulty is worsened if individuals have not established permanent lifestyle or habit changes during therapy.

Significant Interest

Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.

• Adoption is higher among women compared to men.
• The middle-aged age group shows the greatest level of interest.
• A large proportion access the drugs through private prescriptions rather than public health services.

Ultimately, experts emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and long-term success hinges on integrated behavioural changes.